Ranolazine

證據等級: L5

預測適應症: 1 個

Ranolazine: Original Indication Not Documented → Predicted Link to Nephrogenic Syndrome of Inappropriate Antidiuresis

One-Sentence Summary

Ranolazine's original indication and mechanism of action are not available in the current evidence pack, and the drug is not yet marketed in Taiwan. The TxGNN model predicts a possible association with Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD), but this prediction is currently supported by 0 clinical trials and 0 publications — it is a computational signal only.

Quick Overview

Item	Content
Original Indication	Not documented in current evidence (data gap)
Predicted New Indication	Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD)
TxGNN Prediction Score	99.65% (model rank #4278)
Evidence Level	L5
Taiwan Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data for ranolazine is not currently available in this evidence pack, and no original indication is on record either. Without a known MOA, there is no receptor, pathway, or pharmacological basis on which to evaluate whether ranolazine's action could plausibly extend to NSIAD.

NSIAD itself is a rare, X-linked condition caused by gain-of-function mutations in the vasopressin V2 receptor (AVPR2), leading to inappropriate water retention independent of vasopressin levels. Establishing a credible mechanistic link would require evidence that ranolazine interacts with the AVPR2 pathway, renal water-handling mechanisms, or a related target — none of which can be assessed here due to the missing MOA data.

As a result, this prediction rests entirely on the TxGNN model's computed similarity score (99.65%, rank #4278 out of the model's candidate space), with no corroborating clinical trial, registry, or literature evidence. It should be treated as an early-stage hypothesis-generation signal rather than a pharmacologically grounded rationale.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Taiwan Market Information

Ranolazine is not currently marketed in Taiwan (0 product authorizations on record), so no license or product detail table is available.

Safety Considerations

Please refer to the package insert for safety information. (TFDA warnings, contraindications, and DDI data are not currently available for this drug in Taiwan.)

Conclusion and Next Steps

Decision: Hold

Rationale: This candidate is at the earliest possible evaluation stage (S0) — there is no MOA, no documented original indication, no clinical trial or literature support, and no Taiwan market presence. The 99.65% TxGNN score alone is insufficient to justify further evaluation without a mechanistic or empirical basis.

To proceed, the following is needed:

Confirmed original indication(s) and mechanism of action (via DrugBank/manufacturer labeling)
TFDA package insert data on warnings and contraindications (currently a blocking data gap, DG001)
A literature or preclinical search specifically probing any link between sodium-channel/late INa modulation (ranolazine's known pharmacology in other markets) and vasopressin/AVPR2-mediated water retention, to establish or rule out mechanistic plausibility
Ongoing monitoring for any new clinical trial or case-report evidence on ranolazine and NSIAD, given none currently exist
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.